Pharmafile Logo

Myovant

- PMLiVE

Esperion gets FDA thumbs up for cholesterol drug Nexletol

Big comeback after previous trial fail

EISAI

Eisai agrees to pull obesity drug Belviq after safety alert

Weight-loss drug linked to increased risk of cancer

- PMLiVE

Exelixis bounces back with new prostate cancer data

Announces encouraging results after initial trial fail

- PMLiVE

FDA accepts priority review for Merck’s antibiotic combo Recarbrio

If approved would provide new option for hard-to-treat infections

Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603

Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603

Onyx Health

- PMLiVE

J&J gets EMA nod for wider use of Erleada in prostate cancer

Maintains a regulatory lead over rival Xtandi

- PMLiVE

FDA approves Horizon’s thyroid eye disease drug ahead of schedule

First FDA-approved treatment for rare autoimmune condition

- PMLiVE

FDA committee rejects Intellipharmaceutics’ opioid drug Aximris

Verdict closely follows rejection of Nektar’s opioid analgesic

Bristol Myers Squibb logo

FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC

A verdict is expected to be delivered by 15 May

- PMLiVE

Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

If approved would become first targeted therapy for tumour type

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links